Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease

Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease and Its Regulation Mechanism to the Immune Homeostasis Mediated by Th17/Treg Cells

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01697761

Enrollment

Registered

2012-10-02

Start date

2012-09-30

Completion date

2014-11-30

Last updated

2014-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CAM, Crohn's Disease

Keywords

Crohn's disease,acupuncture,moxibustion,inflammation factors

Brief summary

Detailed description

The purpose of this study is to determine whether acupuncture or moxibustion therapies are effective in the treatment of active Crohn's disease. meanwhile, we are aim to observe the content of Inflammatory factors and Neurotransmitter before and after acupuncture and moxibustion therapy. Through treating active Crohn's disease by acupuncture and moxibustion therapies for 12 weeks, we are aim to observe the efficiency and the probably change of Inflammatory factors and Neurotransmitter of colonic mucosa and we may elucidate the mechanism of the efficiency of acupuncture and moxibustion therapy.

Interventions

OTHERTreatment Group

patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks

OTHERControl Group

patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* age 18-70 years; * Crohn's Disease Activity Index \[CDAI\]\>150 and \<450; * not taking any medication or taking salicylates, prednisone ( dose≤ 15mg and at least have taken a month ), after entering the study the dose remained constant; * Not taking immunosuppressive agents or use with biological preparations within 3 months prior to entering the study * signing a written informed consent form.

Exclusion criteria

* Severe Crohn's disease patients or patients in remission ( CDAI \> 450 or \< 150 ); * The pregnancy or lactation period patients ; * patients associated with heart, brain, liver, kidney and hematopoietic system disease; * The psychiatric patients; * Patients with other serious diseases.

Design outcomes

Primary

Measure	Time frame	Description
CDAI	2 years	Crohn's Disease Activity Index

Secondary

Measure	Time frame	Description
Inflammatory factors	2 years	Intestinal mucosa of Th17/Treg,IL-6,IL-17,IL-23,etc
Neurotransmitter	2 years	Intestinal mucosa of 5-HT,DA,SP,VIP and their receptors etc
IBDQ	2 years	Inflammatory Bowel Disease Questionnaire

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026